Vnitr Lek 2021, 67(1):e09-e13 | DOI: 10.36290/vnl.2021.011

Is autoimmune pancreatitis a risk factor for pancreatic adenocarcinoma?

Lumír Kunovský1,2,3, Petr Dítě1,4, Martin Blaho4,5, Jana Dvořáčková5,6, Magdalena Uvírová6, Marie Přecechtělová1,3, Petr Jabandžiev3,7,8, Hana Mašková1,3, Bohuslav Kianička3,9, Pavel Janeček2,3, Michal Eid3,10, Arnošt Martínek4,5
1 Department of Gastroenterology and Internal Medicine, University Hospital Brno, Brno, Czech Republic
2 Department of Surgery, University Hospital Brno, Brno, Czech Republic
3 Faculty of Medicine, Masaryk University, Brno, Czech Republic
4 Department of Internal Medicine, Department of Gastroenterology, University Hospital Ostrava, Ostrava, Czech Republic
5 Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
6 CGB Laboratory, a. s., Ostrava, Czech Republic
7 Department of Pediatrics, University Hospital Brno, Brno, Czech Republic
8 Central European Institute of Technology, Masaryk University, Brno, Czech Republic
9 2
nd Department of Internal Medicine, Department of Gastroenterology, St. Anne's University Hospital, Brno, Czech Republic
10 Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Brno, Czech Republic

Immunoglobulin G4-related diseases (IgG4-RD) are a group of diseases characterized by high serum levels of immunoglobulin G4 (IgG4), increased lymphocyte and plasma cell with IgG4 positivity in the parenchyma of some organs, and storiform fibrosis. The most frequently affected organ is the pancreas. This is an autoimmune form of pancreatitis, which can be divided into two types: Type 1, which is significantly more common than Type 2, is high in IgG4 in the pancreatic parenchyma and shows a fundamental difference in the noted presence of extra­‑pancreatic disorders.

In general, chronic inflammation is a risk factor in the development of carcinomas. Chronic pancreatitis is an accepted risk factor for the development of pancreatic cancer. The question is whether this also applies to autoimmune pancreatitis (AIP), which has some mediators of inflammation in common with sporadic pancreatitis, and what role the presence of IgG4 plays.

The vast majority of the work on this topic consists of case reports, yet, even based on our own experience, we would like to say that there is a relationship between the autoimmune form of pancreatitis and pancreatic cancer, which usually occurs in the first two years after diagnosis of AIP. Also significant is the fact that the group of people with AIP, who is a clinical manifestation of IgG4-RD, was found to have an even higher incidence of extrapancreatic cancer than in the pancreas itself.

Differentiating AIP from pancreatic cancer can sometimes be problematic since these diseases can both present as focal pancreatic lesions. IgG4 has been considered useful for AIP diagnosis, however, IgG4 levels can be slightly elevated, as in the case with pancreatic adenocarcinoma. IgG4 levels of over twice the upper limit are rare among patients with pancreatic adenocarcinoma. However, cases of simultaneous presentation of pancreatic cancer and AIP have been documented and should not be neglected.

Keywords: chronic inflammation, carcinogenesis, autoimmune pancreatitis, chronic pancreatitis, pancreatic adenocarcinoma, immunoglobulin G4.

Published: March 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kunovský L, Dítě P, Blaho M, Dvořáčková J, Uvírová M, Přecechtělová M, et al.. Is autoimmune pancreatitis a risk factor for pancreatic adenocarcinoma? Vnitr Lek. 2021;67(1):e09-13. doi: 10.36290/vnl.2021.011.
Download citation

References

  1. Stone JH, Zen J, Desphande V. Mechanisms of disease. IgG4- related disease. N Engl J Med 2012; 366(6): 539-551. Go to original source... Go to PubMed...
  2. Miyabe K, Zen Y, Cornell LD, et al. Gastrointestinal and Extra‑Intestinal Manifestations of IgG4-Related Disease. Gastroenterology. 2018; 155(4): 990-1003.e1.
  3. Desphande V, Zen Y, Chan JKC et al. Consensus statement on the pathology of IgG4-related disease. Modern Pathol 2012; 25: 1181-1192. Go to original source... Go to PubMed...
  4. Shimosegawa T, Chari ST, Frulloni L et al. International consensus diagnostic criteria for autoimmune pancreatitis, guidelines of the International Association of Pancreatology. Pancreas 2011; 40: 352-358. Go to original source... Go to PubMed...
  5. Paras A. Type I interferon - mediated autoimmune disease: pathogenesis, diagnosis and target therapy. Rheumatology 2017; 66: 1662-1675. Go to original source... Go to PubMed...
  6. Watanabe T, Minaga K, Kamata K. Mechanistic insights into autoimmune pancreatitis. Trends in Immunology 2018; 39(1): 874-889. Go to original source... Go to PubMed...
  7. Hart PA, Zen Y, Chari ST. Recent advances in autoimmune pancreatitis. Gastroenterology 2015; 149: 39-51. Go to original source... Go to PubMed...
  8. Kawa S, Ota M, Yoshizawa K et al. HLA DRB10405 - DQB10401 haplotype is associated with autoimmune pancreatitis in Japanese population. Gastroenterology 2012; 122: 1264-1269. Go to original source... Go to PubMed...
  9. Okazaki K, Uchida K, Fukui T et al. Recent advances in autoimmune pancreatitis. Gastroenterol Hepatol (N Y). 2008; 4(6): 417-426.
  10. Stone JH, Klosroshah A, Desphande V et al. IgG4-Related Disease: Recommendations for the Nomenclature of this Condition and its Individual Organ System Manifestations. Arthritis Rheum 2012; 64: 532-539. Go to original source... Go to PubMed...
  11. Webster GJ. Autoimmune pancreatitis - a riddle wrapped in an enigma. Dig Dis 2016; 34: 532-539. Go to original source... Go to PubMed...
  12. Bojkova M, Dite P, Dvorackova J et al. Immunoglobulin G4, autoimmune pancreatitis and pancreatic cancer. Digestive Disease 2015; 33(1): 86-90. Go to original source... Go to PubMed...
  13. Malka D, Hammel P, Maire F et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002; 51(6): 849-852. DOI: 10.1136/gut.51. 6. 849. Go to original source... Go to PubMed...
  14. Buijs J, Cahen DL, van Heerde MJ et al. The long‑term impact of autoimmune pancreatitis on pancreatic function. Quality of life and life expectancy. Pancreas 2015; 44(7): 1065-1071. Go to original source... Go to PubMed...
  15. Hart PA, Kamisawa T, Brugge WR, et al. Long‑term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013; 62(12): 1771-1776. Go to original source... Go to PubMed...
  16. Ikeura T, Miyoshi H, Uchida K, et al. Relationship between autoimmune pancreatitis and pancreatic cancer: a single‑center experience. Pancreatology. 2014 Sep‑Oct;14(5): 373-379. Go to original source... Go to PubMed...
  17. Ikeura T, Miyoshi H, Shimatani M, et al. Long‑term outcomes of autoimmune pancreatitis. World J Gastroenterol. 2016; 22(34): 7760-7766. doi:10.3748/wjg.v22.i34.7760 Go to original source... Go to PubMed...
  18. Xiang P, Zhang X, Lang Y et al. Pancreatic tumour in type 1 autoimmune pancreatitis: a diagnostic challenge. BMC Cancer 2019; 19: 814. doi.org/1O.1186/s12885-O19-6O27-O Go to original source... Go to PubMed...
  19. Shiokawa M, Kodama Y, Yoshimura K et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol 2013; 108(4): 610-617. Go to original source...
  20. Asano J, Watanabe T, Oguchi T et al. Association between immunoglobulin G4-related disease and malignancy within 12 years after diagnosis: An analysis after longterm followup. J Rheumatol 2015; 42(11): 2135-2142. Go to original source... Go to PubMed...
  21. Hirano K.,Tada M., Sasahira N et al : Incidence of malgnancies in patients with IgG4-related disease- Iternal Med 2O14, 53: 171-176.
  22. Macinga P, Pulkertova A, Bajer L et al. Simultaneous occurrence of autoimmune pancreatitis and pancreatic cancer in patients resected for focal pancreatic mass. WJG 2017; 23(12): 2185-2193. Go to original source... Go to PubMed...
  23. Schneider A, Hirth M, Munch M et al. Risk of cancer in patients with autoimmune pancreatitis.: A singe center experiences from Germany. Digestion 2017; 95: 172-180. Go to original source... Go to PubMed...
  24. Zhang Z, Rigas B. NF‑kappaB, inflammation and pancreatic carcinogenesis: NF‑kappaB as a chemoprevention target (review). Int J Oncology 2006; 29: 185-192. Go to original source...
  25. Fujioka S, Sclabas GM, Schmidt C et al. Inhibition of constitutive NF‑kappaB activity by I kappa B alpha M supresses tumorigenesis. Oncogene 2003; 22: 1365-1370. Go to original source... Go to PubMed...
  26. Garcea G, Neal CP, Pattenden CJ et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41: 2213-2236. Go to original source... Go to PubMed...
  27. Bonizzi G, Karin M. The two NF‑kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-288. Go to original source... Go to PubMed...
  28. Sclaba GM, Uwagawa T, Shmidt C et al. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005; 103: 2485-2490. Go to original source... Go to PubMed...
  29. Chandler NM, Canete JJ, Callery MP. Increased expression of NF‑kappa B in human pancreatic cancer cells. J Surg Res 2004; 118: 9-14. Go to original source... Go to PubMed...
  30. Sclaba GM, Fujoka S, Schmidr C et al. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor kappaB signaling pathway with the anti‑epidermal growth factor antibody IMC‑C 225. J Gastroint Surgery 2003; 7: 37-43. Go to original source... Go to PubMed...
  31. Liptay S, Weber CK, Ludwig L. et al. Mitogenic and anti‑apoptotic role of constitutive NF‑kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003; 105: 735-746. Go to original source... Go to PubMed...
  32. Kamisawa T, Tsuruta K, Okamoto A et al. Frequent and significant K‑ras mutation in the pancreas, the bile duct and the gallbladder in autoimmune pancreatitis. Pancreas 2009; 38(8): 890-895.
  33. Fan Z, Fan K, Yang C, et al. Critical role of KRAS mutation in pancreatic ductal adenocarcinoma. Transl Cancer Res 2018; 7(6): 1728-1736. Go to original source...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.